Publications by authors named "T Kusuyama"
A 48-year-old man presented with several months of dyspnea and edema. He had no medical history. Transthoracic echocardiography showed a large mass in the tricuspid orifice.
View Article and Find Full Text PDFArticle Synopsis
- A trial, STOPDAPT-3, was conducted to compare aspirin monotherapy and clopidogrel monotherapy after short-term dual antiplatelet therapy in patients who underwent percutaneous coronary intervention using drug-eluting stents.
- The study involved 5,833 patients who were followed for 30 days, focusing on cardiovascular events (like heart attacks) and bleeding complications as primary endpoints.
- Results showed that aspirin and clopidogrel monotherapy had similar rates of cardiovascular and bleeding events up to one year after the intervention, indicating both treatments are equally effective in these contexts.
Article Synopsis
- Current guidelines suggest avoiding anticoagulation after PCI for acute coronary syndrome (ACS), but this recommendation lacks strong evidence.
- In a study analyzing outcomes of patients with ACS who did or did not receive post-PCI heparin, those receiving heparin had a significantly higher risk of bleeding and a slightly increased risk of cardiovascular events.
- The use of post-PCI heparin in ACS patients was common, but it was linked to increased bleeding without demonstrating any clear benefit in reducing serious cardiovascular outcomes.
Background: Bleeding rates on dual antiplatelet therapy (DAPT) within 1 month after percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in patients with acute coronary syndrome or high bleeding risk. Aspirin-free strategy might result in lower bleeding early after PCI without increasing cardiovascular events, but its efficacy and safety have not yet been proven in randomized trials.
Methods: We randomly assigned 6002 patients with acute coronary syndrome or high bleeding risk just before PCI either to prasugrel (3.